Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Jan 13, 2011

165_ip_2011-01-13_48641d77-de43-4258-8738-04cd3a44147e.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

29th Annual J.P. Morgan Healthcare Conference

January 12, 2011 San Francisco, CA Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

1. Business Update

2. Financials & Outlook

3. Growth Strategy & Summary

Excellent quarter and fully on track for full-year targets

Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
h
t
r
o
w
R
e
v
e
n
u
e		 \$
2
8
8
9
m
,		 \$
3
0
5
8
m
,		 6
%
i
N
t
e
n
c
o
m
e
i
bu
b
le
F
M
C
A
G
&
Co
K
Ga
A
t
tr
ta
to
a		 \$
2
2
5
m		 \$
2
4
8
m		 %
1
0
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
0
6
7		 \$
0
8
2		 9
%
  • •Strong revenue growth at 7% at constant currency and 6% organic
  • •Very good EBIT margin development
  • •Resulting in net income growth of 10%

Continued excellent revenue growth of 9%cc

\$
U
S
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
t
h
r
o
w		 c
c
N
h
A
i
t
o
r
m
e
r
c
a		 1
1
7
4
,		 1
8
6
3
,		 %
7
I
i
l
t
t
n
e
r
n
a
o
n
a		 0
6
4		 5
4
8		 1
3
%		 1
%
7
T
l
t
o
a		 2
1
4
7
,		 2
3
2
1
,		 %
8		 %
9
  • •Very good organic treatment growth of 4.7% globally
  • •Continued strong revenue per treatment development
  • •Treating 210,191 patients in 2,716 clinics

cc = constant currency

Further improved performance in all key metrics

Q
3
2
0
1
0		 T
l
t
o
a		 N
h
A
i
t
o
r
m
e
r
c
a		 I
i
l
t
t
n
e
r
n
a
o
n
a
O
i
h
t
r
g
a
n
c
r
e
v
e
n
u
e
g
r
o
w		 %
7		 %
7		 6
%
S
k
h
t
t
t
t
t
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w		 4
%
7		 4
3
%		 6
%
5
R
t
t
t
e
e
n
e
p
e
r
r
e
a
m
e
n
v
u		 *
\$
3
5
1		 \$
1
6
5
c
c
S
t
b
3
0
2
0
1
0
e
p
e
m
e
r
,
N
b
f
l
i
i
m
e
r
o
c
n
c
s
u		 2
7
1
6
,		 1
8
0
9
,		 9
0
7
G
h
t
r
o
w		 8
%		 3
%		 1
9
%
D
e
n
o
o
s
v		 7
2		 4
2		 3
0

* including Mexico

Continued improvement of patient outcomes

N
h
A
i
(
U
S
)
t
o
r
m
e
r
c
a		 E
M		 E
A
%
f
i
t
t
o
p
a
e
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 Q
3
2
0
0
9		 Q
3
2
0
1
0
K
/
V
1
2
t
≥		 9
6
%		 9
6
%		 9
%
5		 5
9
%
H
l
b
i
1
0
1
2
/
d
l
e
m
o
g
o
n
g
=
-		 6
4
%		 6
9
%		 3
%
5		 5
4
%
H
l
b
i
1
0
1
3
/
d
l
e
m
o
g
o
n
g
=
-		 8
7
%		 8
8
%		 7
6
%		 6
%
7
A
l
b
i
3
/
d
l
5
≥
u
m
n
g		 8
2
%		 8
2
%		 8
%
7		 8
6
%
P
h
h
t
3
5
5
5
/
d
l
o
s
p
a
e
m
g
-		 %
5
4		 5
%
7		 %
6
0		 6
1
%
H
i
t
l
i
t
i
d
o
s
p
a
z
a
o
n
a
y
s		 1
0
0		 *
9
8		 8
7		 9
4

The hospitalization rates for the US reflects adoption of CMS policy *

Stable reimbursement environment

Product growth in North America impacted by mix shift

\$
S
U
i
l
l
i
m
o
n
s		 Q
3
2
0
0
9		 Q
3
2
0
1
0		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
v
e
n
u
e
(
)
inc
l.
in
te
l r
rn
a
ev
en
ue		 1
0
0
3
,		 1
0
1
8
,		 %
2		 %
4
E
l
t
e
r
n
a
r
e
e
n
e
x
v
u		 2
7
4		 7
3
7		 1
%
-		 3
%
N
h
A
i
t
o
r
m
e
r
c
a		 2
0
9		 2
0
8		 0
%
I
t
t
i
l
n
e
r
n
a
o
n
a		 5
3
3		 5
2
9		 %
1
-		 %
4

cc = constant currency

Product Launches

Liberty Cylcler F250 - Optiflux Delflex – neutral pH 2008 K-Sorb2008 T 5008 S

1. Business Update

2. Financials & Outlook

3. Growth Strategy & Summary

Total revenue increased by 8%cc to \$8,886 m

\$
S
U
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 9
M
2
0
1
0		 G
h
t
r
o
w
N
t
e
r
e
e
n
e
v
u		 8
2
1
2
,		 8
8
8
6
,		 *
%
8
O
(
)
t
i
i
E
B
I
T
p
e
r
a
n
g
n
c
o
m
e		 1
2
6
5
,		 5
1
3
8
,		 1
0
%
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
4
5		 1
6
5
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e
n
e
,		 2
2
5		 2
0
6
f
I
b
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 1
0
4
0
,		 1
1
7
9
,		 1
3
%
I
t
n
c
o
m
e
a
e
p
e
n
s
e
x
x		 3
4
5		 4
1
0
T
t
a
r
a
e
x		 %
3
3		 %
3
5
N
t
l
l
i
i
t
t
o
n
-c
o
n
r
o
n
g
n
e
r
e
s		 5
0		 6
2
N
t
i
e
n
c
o
m
e
i
bu
b
le
F
M
C
A
G
&
Co
K
Ga
A
t
tr
ta
to
a		 6
4
5		 7
0
7		 1
0
%

* 8% growth at constant currency, 6% organic growth

Operating cash flow above \$ 1 billion and at 12% of revenue

\$
S
U
i
l
l
i
m
o
n
s		 9
M
2
0
0
9		 9
M
2
0
1
0		 G
h
t
r
o
w
1)
O
i
h
f
l
t
p
e
r
a
n
g
c
a
s
o
w		 8
8
0		 1
0
2
7
,
1
2
%
f r
o
ev
e
nu
e		 1
7
%
1)
C
i
t
l
d
i
t
t
a
p
a
e
x
p
e
n
u
r
e
s
n
e
,		 (
3
8
8
)		 (
)
3
3
9
f
F
h
l
r
e
e
c
a
s
o
w		 4
9
2		 6
8
8
8
%
f r
o
ev
e
nu
e		 4
0
%
1)
2)
A
i
i
i
t
f
d
i
i
c
q
s
o
n
s
t
t
t
u
n
e
o
v
e
s
u
r
e
s
,		 (
1
0
7
)		 (
2
3
9
)
1)
2)
f
F
h
l
f
t
i
i
t
i
r
e
e
c
a
s
o
w
a
e
r
a
c
q
u
s
o
n
s
,		 3
8
5		 4
4
9

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

2) Does not include a \$131 m cash out for a short-term bank deposit in Q2 2010 and a cash repayment in form of an inter-company loan of \$ 50 m in Q2 2009

2010 GUIDANCE – Outlook improved

Fully on track for 2010 Targets

\$
U
S
i
l
l
i
m
o
n
s		 G
i
d
a
n
c
e
u
N
t
e
r
e
v
e
n
u
e		 \$
1
2
0
0
0
>
,
N
i
t
i
d
e
n
c
o
m
e
m
p
r
o
e
v
C
G
&
Co
Ga
t
tr
i
bu
ta
b
le
to
F
M
A
K
A
a		 \$
9
6
0
9
8
0
-
L
i
t
e
e
r
a
g
e
r
a
o
v
(
D
b
/
E
B
I
T
D
A
)
t
e		 2
5
<
C
i
l
d
i
t
t
a
p
a
e
x
p
e
n
u
r
e
s		 \$
5
5
0
6
5
0
-
A
i
i
i
t
c
q
u
s
o
n
s		 \$
0
0
5
t
u
p
o

1. Business Update

2. Financials & Outlook

3. Growth Strategy & Summary

Development of Dialysis Patient Population

  • Renal failure persists worldwide
  • Dialysis is the primary treatment modality on a global scale
  • The number of global dialysis patients is expected to increase 36% by 2015

Market Opportunity by Region

Continued Growth Opportunities

Strategic Accomplishments in 2010

E
u
r
o
p
e		 X
X
X
X		 f
A
i
i
t
i
K
d
1
0
0
0
t
i
t
i
R
i
c
q
u
s
o
n
o
r
a
s
n
o
a
r
p
a
e
n
s
n
u
s
s
a
,
F
M
C
/
G
l
i
J
V
R
l
P
h
a
e
n
c
a
e
n
a
a
r
m
a
–
f
A
i
i
t
i
E
d
i
8
0
0
0
t
i
t
i
E
t
E
c
q
u
s
o
n
o
u
r
o
m
e
c
p
a
e
n
s
n
a
s
e
r
n
u
r
o
p
e
,
G
b
P
D
B
i
a
m
r
o
u
s
n
e
s
s
A
i
s
a		 X f
C
A
i
i
t
i
A
i
R
l
d
d
i
6
2
0
0
t
i
t
i
c
q
u
s
o
n
o
s
a
e
n
a
a
r
e
a
n
g
p
a
e
n
s
n
m
o
r
e
,
t
h
1
0
0
l
i
i
a
n
c
n
c
s
  • X Long-term distribution agreement with Nikkiso expanding dialysis products business in Korea
  • X Gambro PD Business

Pacific

Growth Strategy Implementation 23 Countries Account for > 92% of Revenue

N
h
A
i
t
o
r
m
e
r
c
a		 S
(
)
i
2
0
1
0
e
r
c
e
s
v		 P
d
t
r
o
c
s
u
C
d
a
n
a
a		 9 9
M
i
e
x
c
o		 9 9
S
U
A		 9 9
E
M
E
A
C
h
R
b
l
i
z
e
c
e
p
u
c		 9
+		 9
F
r
a
n
c
e		 9 9
G
e
r
m
a
n
y		 9 9
I
l
t
a
y		 9 9
P
l
t
o
r
u
g
a		 9
+		 9
S
i
p
a
n		 9
+		 9
U
i
d
K
i
d
t
n
e
n
g
o
m		 9
+		 9
T
k
u
r
e
y		 9
+		 9
P
l
d
o
a
n		 9
+		 9
R
i
u
s
s
a		 9
+		 9
i
R
o
m
a
n
a		 9
+		 9
A
i
P
i
f
i
s
a
a
c
c
A
l
i
t
u
s
r
a
a		 9 9
C
h
i
n
a		 9
+		 9
H
K
o
n
g
o
n
g		 9
+		 9
J
a
p
a
n		 9
+		 9
K
o
r
e
a		 9
+		 9
T
i
a
w
a
n		 9
+		 9
L
i
A
i
t
a
n
m
e
r
c
a
A
i
t
r
g
e
n
n
a		 9 9
i
B
l
r
a
z		 9 9
C
l
b
i
o
o
m
a		 9 9

Rationale for ESRD Integrated Care Model

Product

Services

Renal Pharma / Therapy

• Combine membrane, drug delivery and laboratory technology with proven dialysis drugs to provide superior outcomes

Integrated Care Looking Ahead to ACO

Thank you for your interest in Fresenius Medical Care

More from Fresenius Medical Care AG & Co. KGaA

Regulatory Filings 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.